$CKPT News
Last published 11mo ago
- 11mo agoCKPTApproval of Unloxcyt, Bla #761297FDA Approved DrugsApproval Date: 11/21/2025; Drug Name: Unloxcyt, Bla #761297; Active Ingredients: COSIBELIMAB-IPDL; Company: Checkpoint Therapeutics Inc; Submission Status: Approval; Application Number: 761297
- 1y agoCKPTDERMFBIOFBIOPFortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireEmrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint
- 1y agoCKPTFBIOCheckpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate UpdatesGlobeNewswireUNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merger to
- 1y agoCKPTDERMFBIOFBIOPFortress Biotech Reports 2024 Financial Results and Recent Corporate HighlightsGlobeNewswireEmrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint
- 1y agoCKPTFBIOCheckpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate UpdatesGlobeNewswireWALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the
- 1y agoCKPTFBIOCKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun PharmaPR NewswireShareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun...
- 1y agoCKPTFBIOSun Pharma to Acquire Checkpoint TherapeuticsPR NewswireSun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or...
- 1y agoONCYCRDFPSNLTEM+1Oncology Advancements Accelerate Amid Rising Early-Onset Cancer DiagnosesPR NewswireUSA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring major...
- 1y agoCKPTFBIOCheckpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)GlobeNewswireWALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), today announced that the U.S. Food and Drug Administration ("FDA") has approved
- 1y agoONCYAKYACKPTBCTX+1Biotech Advances Drive Cancer Research as Global Rates Continue Upward TrendPR NewswireUSA News Group News Commentary – Despite death rates for some cancers being on the decline, there is a global surge in cancer cases among people...
- 1y agoCKPTDERMFBIOFBIOPFortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswireEmrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally advanced cutaneous
- 1y agoCKPTFBIOCheckpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate UpdatesGlobeNewswireBiologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint")
- 2y agoCKPTFBIOCheckpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024GlobeNewswireWALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the presentation of
- 2y agoCKPTFBIOCheckpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireWALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero,
- 2y agoATXICKPTDERMFBIO+1Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswirePDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to treat metastatic or
- 2y agoCKPTFBIOCheckpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate UpdatesGlobeNewswireWALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the
- 2y agoCKPTFBIOCheckpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell CarcinomaGlobeNewswireWALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug
- 2y agoCKPTFBIOGC Cell and Checkpoint Therapeutics Advance Collaborative Cancer ResearchGlobeNewswireCollaboration explores the potential synergistic effects of Checkpoint's anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024
- 2y agoCKPTFBIOCheckpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireWALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a
- 2y agoCKPTFBIOCheckpoint Therapeutics Announces Biologics License Application Resubmission for CosibelimabGlobeNewswireWALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has completed the
- 2y agoCKPTFBIOCheckpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA ResubmissionGlobeNewswireWALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has reached alignment with
- 2y agoCKPTINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointGlobeNewswireNEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company")
- 2y agoCKPTDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. ("Checkpoint"...
- 2y agoCKPTSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointGlobeNewswireNEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company")
- 2y agoCKPTDERMFBIOFortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswireFortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 FDA accepted New Drug
- 2y agoCKPTFBIOCheckpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceGlobeNewswireWALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President
- 2y agoCKPTFBIOCheckpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesGlobeNewswireWALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first
- 2y agoCKPTSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointGlobeNewswireNEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company")
- 2y agoCKPTINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointGlobeNewswireNEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company")
- 2y agoCKPTSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CheckpointGlobeNewswireNEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company")
- 2y agoCKPTDERMFBIOMBIOFortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireRecord consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application filing for DFD-29 to
- 2y agoCKPTFBIOCheckpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireWALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the
- 2y agoCKPTFBIOCheckpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of DirectorsGlobeNewswireWALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit
- 2y agoCKPTFBIOCheckpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-MarketGlobeNewswireWALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a
- 2y agoCKPTFBIOCheckpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology ConferenceGlobeNewswireWALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President
- 2y agoCKPTU.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party ManufacturerGlobeNewswireWALTHAM, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), today announced that the U.S. Food and Drug Administration ("FDA") has issued a complete response letter
- 2y agoCKPTFBIOCheckpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent IssuanceGlobeNewswireUpcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint")
- 2y agoCKPTFBIOCheckpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireBiologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 Recent publication of cosibelimab pivotal trial results in the Journal for ImmunoTherapy of Cancer
- 3y agoCKPTFBIOCheckpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of CancerGlobeNewswireCosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous squamous cell
- 3y agoCKPTFBIOCheckpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross ProceedsGlobeNewswireWALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the entry into a definitive
- 3y agoCKPTFBIOCheckpoint Therapeutics to Participate in the Cantor Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero,
- 3y agoCKPTFBIOCheckpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireWALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero,
- 3y agoCKPTFBIOCheckpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireBiologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024 Longer-term cosibelimab results demonstrate substantial
- 3y agoATXICKPTDERMFBIO+1Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireTotal net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29
- 3y agoCKPTFBIOCheckpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-MarketGlobeNewswireWALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a
- 3y agoCKPTFBIOCheckpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell CarcinomaGlobeNewswire55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate in metastatic cSCC Cosibelimab continues to demonstrate a favorable safety
- 3y agoCKPTFBIOCheckpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval DosingGlobeNewswireResults support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024
- 3y agoCKPTFBIOCheckpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireWALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a
- 3y agoCKPTFBIOCheckpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireWALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first
- 3y agoATXICKPTDERMFBIO+1Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewswireFortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023 PDUFA goal date of January 3, 2024 set by FDA for cosibelimab to treat metastatic or locally advanced